LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN): Is the Pharma Giant Undervalued After Recent Share Price Dip?
AstraZeneca (LSE:AZN) shares have dipped slightly over the past week, down 1%, despite steady revenue and net income growth for the pharma giant. Investors seem to be weighing recent performance against the company’s longer-term returns and valuation.
See our latest analysis for AstraZeneca.
Zooming out, AstraZeneca’s 16.3% share price gain so far this year, coupled with a solid 14.4% total shareholder return over the past twelve months, reflects the market’s optimism about its growth...